Population pharmacokinetics of arbekacin, vancomycin, and panipenem in Neonates

被引:69
|
作者
Kimura, T
Sunakawa, K
Matsuura, N
Kubo, H
Shimada, S
Yago, K
机构
[1] Kitasato Univ Hosp, Dept Pharm, Kanagawa 2288555, Japan
[2] Kitasato Univ Hosp, Div Neonatol, Kanagawa 2288555, Japan
[3] Kitasato Univ, Div Infect Dis, Sch Med, Kanagawa 2288555, Japan
[4] Kitasato Univ, Sch Pharmaceut Sci, Analyt Chem Lab, Minato Ku, Tokyo 1088641, Japan
关键词
D O I
10.1128/AAC.48.4.1159-1167.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Immature renal function in neonates requires antibiotic dosage adjustment. Population pharmacokinetic studies were performed to determine the optimal dosage regimens for three types of antibiotics: an aminoglycoside, arbekacin; a glycopeptide, vancomycin; and a carbapenem, panipenem. Eighty-three neonates received arbekacin (n=41), vancomycin (n=19), or panipenem (n=23). The postconceptional ages (PCAs) were 24.1 to 48.4 weeks, and the body weights (BWs) ranged from 458 to 5,200 g. A one-compartment open model with first-order elimination was applied and evaluated with a nonlinear mixed-effect model for population pharmacokinetic analysis. In the fitting process, the fixed effects significantly related to clearance (CL) were PCA, postnatal age, gestational age, BW, and serum creatinine level; and the fixed effect significantly related to the volume of distribution (V) was BW. The final formulas for the population pharmacokinetic parameters are as follows: CLarbekacin=0.0238 x BW/serum creatinine level for PCAs of <33 weeks and CLarbekacin=0.0367 x BW/serum creatinine level for PCAs of >= 33 weeks, V-arbekacin=0.54 liters/kg, CLvancomycin=0.0250 x BW/serum creatinine level for PCAs of <34 weeks and CLvancomycin=0.0323 x BW/serum creatinine level for PCAs of greater than or equal to34 weeks, V-vancomycin=0.66 liters/kg, CLpanipenem=0.0832 for PCAs of <33 weeks and CLpanipenem=0.179 x BW for PCAs of >= 33 weeks, and V-panipenem=0.53 liters/kg. When the CL of each drug was evaluated by the nonlinear mixed-effect model, we found that the mean CL for subjects with PCAs of <33 to 34 weeks was significantly smaller than those with PCAs of greater than or equal to33 to 34 weeks, and CL showed an exponential increase with PCA. Many antibiotics are excreted by glomerular filtration, and maturation of glomerular filtration is the most important factor for estimation of antibiotic clearance. Clinicians should consider PCA, serum creatinine level, BW, and chemical features when determining the initial antibiotic dosing regimen for neonates.
引用
收藏
页码:1159 / 1167
页数:9
相关论文
共 50 条
  • [31] Pharmacokinetics of vancomycin in (pre)term neonates and influence of covariates
    De Beer, EFG
    Stolk, LML
    Degraeuwe, PLJ
    Nieman, F
    De Boer, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 555 - 555
  • [32] Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children
    Keith A. Rodvold
    Julie A. Everett
    Randy D. Pryka
    Donna M. Kraus
    Clinical Pharmacokinetics, 1997, 33 : 32 - 51
  • [33] An External Evaluation of Vancomycin Pharmacokinetics Among Septic Neonates
    Bhongsatiern, J.
    Sherwin, C. M. T.
    Stockmann, C.
    Yu, T.
    Reith, D. M.
    Desai, P. B.
    Spigarelli, M. G.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 664 - 664
  • [34] POPULATION PHARMACOKINETICS OF GENTAMICIN IN NEONATES
    THOMSON, AH
    WAY, S
    BRYSON, SM
    MCGOVERN, EM
    KELMAN, AW
    WHITING, B
    DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1988, 11 (03): : 173 - 179
  • [35] Population pharmacokinetics of cisapride in neonates
    F. Odoul
    C. Le Guellec
    A. Henrot
    E. Saliba
    J. Levron
    M. Saux
    G. Paintaud
    E. Autret-Leca
    European Journal of Clinical Pharmacology, 2002, 58 : 507 - 513
  • [36] Population pharmacokinetics of cisapride in neonates
    Odoul, F
    Le Guellec, C
    Henrot, A
    Saliba, E
    Levron, JC
    Saux, MC
    Paintaud, G
    Autret-Leca, E
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (08) : 507 - 513
  • [37] Tobramycin population pharmacokinetics in neonates
    deHoog, M
    Schoemaker, RC
    Mouton, JW
    vandenAnker, JN
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) : 392 - 399
  • [38] Population pharmacokinetics of nalbuphine in neonates
    Jacqz-Aigrain, E
    Debillon, T
    Daoud, P
    Hamon, I
    Popon, M
    Mentre, F
    PEDIATRIC RESEARCH, 2000, 47 (04) : 471A - 471A
  • [39] Population pharmacokinetics of phenobarbital in neonates
    Guillaume, C
    Stolk, L
    Degraeuwe, P
    Beysens, T
    THERAPEUTIC DRUG MONITORING, 2005, 27 (02) : 220 - 220
  • [40] POPULATION PHARMACOKINETICS OF MIDAZOLAM IN NEONATES
    BURTIN, P
    JACQZAIGRAIN, E
    GIRARD, P
    LENCLEN, R
    MAGNY, JF
    BETREMIEUX, P
    TEHIRY, C
    DESPLANQUES, L
    MUSSAT, P
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) : 615 - 625